Fibrinogen-based tissue adhesive
The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
1. A tissue adhesive comprising a therapeutically effective amount of fibrinogen and eglin.
2. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is comprised of human proteins.
3. A tissue adhesive as set forth in claim 1 , wherein the ratio in weight of said eglin to said fibrinogen is from 1:100 to 1:150,000.
4. A tissue adhesive as set forth in claim 1 , wherein the ratio in weight of said eglin to said fibrinogen is from 1:500 to 1:110,000.
5. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive contains at least 10 −6 U of eglin per gram of fibrinogen.
6. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive contains from between 10 −3 and 10 U of eglin per gram of fibrinogen.
7. A tissue adhesive as set forth in claim 1 , further comprising plasminogen in an amount of at least 0.0001 mg/mg of fibrinogen.
8. A tissue adhesive as set forth in claim 7 , wherein said plasminogen is contained in an amount of at least 0.001 mg/mg of fibrinogen.
9. A tissue adhesive as set forth in claim 7 , wherein said plasminogen is contained in an amount of more than 0.01 mg/mg of fibrinogen.
10. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is free from kininogenic proteins.
11. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is resistant to lysis in an environment with high activity for a period of time which is at least 10 hours.
12. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is resistant to lysis in an environment with high fibrinolytic activity for a period of time which is at least 15 hours.
13. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is lyophilized.
14. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is present in solution.
15. A tissue adhesive as set forth in claim 14 , wherein said solution is deep-frozen.
16. A tissue adhesive as set forth in claim 1 , wherein said tissue adhesive is present in virus-inactivated form.
17. A tissue adhesive as set forth in claim 1 , wherein said eglin is of recombinant origin.
18. A method for treating wounds or hemorrhages with high fibrinolytic activity in patients, comprising administering an effective dose of the tissue adhesive preparation of claim 1 .
19. A method as set forth in claim 18 , wherein said wound or hemorrhage is urological.
20. A method for treating wounds or hemorrhages in patients, comprising administering an effective dose of the tissue adhesive of claim 1 .
21. A method as set forth in claim 20 , wherein said wound or hemorrhage is urological.